Vaccine News and Research

Latest Vaccine News and Research

Pro-vaccination views, higher public health credibility can be vectors of misinformation

In a new paper published in the Harvard Kennedy School Misinformation Review, researchers from the George Washington University, University of Maryland and Johns Hopkins University assessed content from the most active vaccine-related accounts on Twitter and found that even accounts with pro-vaccination views and higher public health credibility can be vectors of misinformation in the highly uncertain and rapidly changing environment caused by the COVID-19 pandemic.

10 Sep 2020

Most adults wary of taking any vaccine approved before the election

The public is deeply skeptical about any coronavirus vaccine approved before the November election, and only 42% would be willing to get a vaccine in that scenario, according to a new poll.

10 Sep 2020

Study: Small proteins block interaction between SARS-CoV-2 and human cell receptor

Using innovative computer-based approaches, researchers have developed protein inhibitors that block the interaction between the SARS-CoV-2 virus and human cell receptor ACE2.

10 Sep 2020

Researchers receive $1.9 million federal grant to find Lyme disease vaccine

Pesky, yet dangerous ticks are no longer latching exclusively onto hunters and outdoor enthusiasts. Milder winters and disrupted habitats have driven them out of the woods, with Lyme disease cases in the United States tripling since the late 1990s.

9 Sep 2020

Pfizer, BioNTech COVID-19 vaccine candidate shows promise in preclinical study

Researchers in the United States and Germany have conducted a study demonstrating the preclinical efficacy of a new candidate vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

9 Sep 2020

Researchers discover a new way to limit inflammation from adjuvants in vaccines

Adjuvants are a key ingredient of many modern vaccines, working to unleash an immune response that helps protect the body from disease. Many scientists believe that adjuvants are they key to developing new kinds of vaccines for hard-to-vaccinate viruses, like HIV.

9 Sep 2020

AstraZeneca COVID-19 vaccine trial paused due to suspected adverse reaction

The coronavirus disease (COVID-19) pandemic is rippling across the globe, with over 27.47 million reported cases. With the vast spread of the virus, scientists are racing to gain the approval of candidate vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19 disease and Multisystem Inflammatory Syndrome in Children (MIS-C).

8 Sep 2020

Memory B cells indicate durable immunity in COVID-19

Now a new study by researchers at SUNY Upstate Medical University and published recently on the preprint server medRxiv in September 2020 shows that memory B cells are upregulated in convalescent COVID-19 patients, correlating with a better immune response and shorter symptom duration.

8 Sep 2020

Scientists develop a rapid, reliable and low-cost COVID-19 antibody test

Robust and widespread antibody testing has emerged as a key strategy in the fight against SARS-CoV-2, the virus responsible for the COVID-19 pandemic.

8 Sep 2020

Tel Aviv University receives philanthropic grant from 3M for COVID-19 vaccine research

Science-based technology company 3M has awarded a significant philanthropic research grant of $400,000 to the Shmunis School of Biomedicine and Cancer Research at Tel Aviv University to advance scientific knowledge in the global response to the COVID-19 pandemic.

8 Sep 2020

With schools starting online, vaccinations head for recess

As co-director of school-based health centers at Bassett Healthcare Network, the pediatrician oversees about 21 school-based health clinics across the region — a poor, rural area known for manufacturing and crippled by the opioid epidemic.

8 Sep 2020

Study finds strong T cell responses in patients recovered from COVID-19

Oxford University researchers have found that natural infection with COVID-19 produces a robust T cell response, including inducing T cell ‘memory’ to potentially fight future infections.

8 Sep 2020

Scientists describe various dynamic structures of the SARS-CoV-2 spike protein

Early in the pandemic, scientists uncovered the role of the ACE2 receptor in SARS-CoV-2, the virus that causes the coronavirus disease (COVID-19). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and the angiotensin-converting enzyme 2 (ACE2) receptors act as a lock and key for cell infection.

7 Sep 2020

Consortium compiles recommendations for measuring HIV reservoir size in cure-directed studies

Spearheaded by scientists at The Wistar Institute, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

7 Sep 2020

Important research on SARS-CoV-2 proteins using proximity labeling

A team of Canadian scientists has recently discovered a wide-range interaction between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and host proteins using proximity-dependent biotinylation approaches.

7 Sep 2020

Novel RNA vaccine from Arcturus Therapeutics protects mice against SARS-CoV-2

A new study published on the preprint server bioRxiv in September 2020 reports a novel RNA vaccine platform that shows robust protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in mice and performs much better than a conventional mRNA vaccine. This could allow single-dose immunization, allowing progress towards global vaccination.

6 Sep 2020

Seasonal influenza and COVID-19 risk

In a new study published on the preprint server medRxiv, researchers from Laval University and McGill University in Canada reviewed evidence from 18 relevant studies on a possible interaction between influenza vaccines on non-influenza respiratory disease (NIRD).

6 Sep 2020

Study shows SARS-CoV-2 cell receptor is a novel target of the gamma-secretase enzyme complex

Based on structural similarities with other targets of the gamma-secretase system, researchers from Columbia University Irving Medical Center in the United States show that the SARS-CoV-2 receptor for cell entry may be affected by its proteolytic activity. Their results are currently freely available in a bioRxiv preprint paper.

6 Sep 2020

Antibody responses against seasonal common cold coronaviruses may protect against SARS-CoV-2

With the use of an accurate high throughput assay, researchers from the Weizmann Institute of Science and Magen David Adom Blood Services in Israel showed substantial inter-individual variability and antibody cross-reactivity against seasonal coronaviruses upon SARS-CoV-2 infection, with important implications for immune surveys and vaccines. The study is currently available on the medRxiv* preprint server.

6 Sep 2020

Early-phase Russian trials reveal safety and immunogenicity of two formulations of a two-part vaccine

Results from two early-phase Russian non-randomised vaccine trials (Sputnik V) in a total of 76 people are published today in The Lancet, finding that two formulations of a two-part vaccine have a good safety profile with no serious adverse events detected over 42 days, and induce antibody responses in all participants within 21 days.

5 Sep 2020